About CytoVale
CytoVale is a company based in San Francisco (United States) founded in 2013. CytoVale has raised $206.78 million across 15 funding rounds from investors including HHS, CPP Investments and Norwest Venture Partners. The company has 115 employees as of December 31, 2024. CytoVale offers products and services including IntelliSep Sepsis Test. CytoVale operates in a competitive market with competitors including OpGen, Avails Medical, SphingoTec, Abionic and NOWDiagnostics, among others.
- Headquarter San Francisco, United States
- Employees 115 as on 31 Dec, 2024
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cytovale Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$206.78 M (USD)
in 15 rounds
-
Latest Funding Round
$100 M (USD), Series D
Oct 11, 2024
-
Investors
HHS
& 12 more
-
Employee Count
115
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CytoVale
CytoVale offers a comprehensive portfolio of products and services, including IntelliSep Sepsis Test.
Rapid test assesses sepsis risk using white blood cell analysis.
People of CytoVale
Unlock access to complete
Unlock access to complete
Funding Insights of CytoVale
CytoVale has successfully raised a total of $206.78M across 15 strategic funding rounds. The most recent funding activity was a Series D round of $100 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CytoVale
CytoVale has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, CPP Investments and Norwest Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital and growth equity firm providing investments and resources to entrepreneurs in various sectors.
|
Locked | Locked | Locked | |
|
Venture debt is provided globally across multiple sectors.
|
Locked | Locked | Locked | |
|
Early-stage investments in science-driven companies are made.
|
Locked | Locked | Locked |
Investor details for CytoVale
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CytoVale
Investment portfolio details for CytoVale
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CytoVale
Detailed financials for CytoVale
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cytovale Comparisons
Peer comparison for CytoVale
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CytoVale
CytoVale operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as OpGen, Avails Medical, SphingoTec, Abionic and NOWDiagnostics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of diagnostics and bioinformatics platforms for providers
|
|
| Locked | Locked | Locked |
Point-of-care devices are developed for infection diagnosis and treatment optimization.
|
|
| Locked | Locked | Locked |
Biomarker-based diagnostic solutions for cancer and cardiovascular diseases are developed.
|
|
| Locked | Locked | Locked |
Point-of-care diagnostic tools for allergy profiles are provided.
|
|
| Locked | Locked | Locked |
Develops rapid assay medical tests that use a single drop of blood to test for a variety of common conditions, illnesses and diseases
|
Detailed competitors of CytoVale
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cytovale
Complete news archive for CytoVale
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CytoVale
CytoVale was founded in 2013.
CytoVale is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
CytoVale is a funded company, having raised a total of $206.78M across 15 funding rounds to date.
As of Dec 31, 2024, the latest employee count at CytoVale is 115.
CytoVale is focussed on developing biomarkers for the early detection of sepsis, an infectious reaction that can lead to lung, kidney and liver failure. Its technology is based on the mechanical properties of individual cells (mechanomics). The instrument uses microfluidics to route and physically probe individual cells and claims to have the capacity to measure over 10 biophysical cell markers at rates above 2k cells per second, providing a high-throughput detection of the disease.
CytoVale's top competitors include Abionic, Avails Medical and SphingoTec.
CytoVale offers IntelliSep Sepsis Test.
CytoVale has 13 investors. Key investors include HHS, CPP Investments, Norwest Venture Partners, Western Technology Investment, and EMV Capital.